Puma Biotechnology (PBYI) has provided an update.
At the 2024 Annual Meeting, stockholders of the Company made key decisions regarding leadership and financial governance. Eight directors were elected to serve for one year, KPMG LLP was ratified as the independent accounting firm for the year, and an advisory vote approved executive compensation terms. Additionally, stockholders agreed to hold future advisory votes on executive compensation annually and approved an amendment to increase the common stock reserved for the Incentive Award Plan by 3 million shares.
See more data about PBYI stock on TipRanks’ Stock Analysis page.
